Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease (MDEBMIC)

Centre Hospitalier Universitaire, Amiens

Status: Completed

Conditions: Gastrointestinal Disease; Biotherapy; Pediatric Disorder; Rheumatology; Ophthalmology; Chronic Inflammatory Disease; Allergic Skin Reaction; Dermatologic Complication

Treatments: Other: dermatological consultation

Study type: Observational

Funder types: Other

Identifiers

NCT04327752

PI2018_843_0048

Details and patient eligibility

About

Biological treatments (BT) are commonly prescribed to treat chronic inflammatory diseases in children. Paradoxical reactions during treatment with a biological agent can be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition. Limited data are available in children treated by BT on cutaneous paradoxical reactions, or any other cutaneous adverse events occurring during treatment. On the contrary, dermatologists tend to see and manage increasing numbers of cutaneous adverse events, including paradoxical reactions. The aim of this project is to describe the incidence of cutaneous adverse events, including cutaneous paradoxical reactions, occurring in the pediatric population, during a treatment by BT given for a chronic inflammatory disease.

Enrollment: 20 patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children under 18 years old
• Children treated by biotherapy among : Adalimumab, Golimumab, Infliximab, Ustekinumab, Etanercept, Tocilizumab, Canakinumab, Anakinra, Abatacept.
• Children treated for a chronic inflammatory disease (rheumatologic, gastro-enterologic, dermatologic and ophthalmologic)
• Children treated in the CHU of Amiens
• Parental consent signed

Exclusion criteria

• Age > 18 ans